EAU Guidelines on Prostate Cancer

• Published in: European urology Vol. 48; no. 4; pp. 546 - 551
• Main Authors: Aus, G., Abbou, C.C., Bolla, M., Heidenreich, A., Schmid, H.-P., van Poppel, H., Wolff, J., Zattoni, F.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier B.V 01.10.2005; Elsevier
• Subjects: Biological and medical sciences; Clinical Trials as Topic; Diagnosis; EAU guidelines; Europe - epidemiology; Follow-up; Gynecology. Andrology. Obstetrics; Humans; Male; Male genital diseases; Medical sciences; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; Nephrology. Urinary tract diseases; Prostate cancer; Prostatic Neoplasms - classification; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - therapy; Review; Risk Factors; Treatment; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Europe; EAU guidelines; Treatment; Review; Diagnosis; Prostate cancer; Follow-up; Nephrology; Urinary system disease; Prostate disease; Malignant tumor; Recommendation; Urology; Male genital diseases; Bibliographic review
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2005.06.001

The first summary of the European Association of Urology (EAU) guidelines on prostate cancer was published in 2001. These guidelines have been continuously updated since many important changes affecting the clinical management of patients with prostate cancer have occurred over the past years. The aim of this paper is to present a summary of the 2005 update of the EAU guidelines on prostate cancer. A literature review of the new data has been performed by the working panel. The guidelines have been updated and level of evidence/grade of recommendation added to the text. This enables readers to better understand the quality of the data forming the basis of the recommendations. A full version is available at the EAU Office or at www.uroweb.org. Systemic prostate biopsies under ultrasound guidance is the preferred diagnostic method and the use of periprostatic injection of a local anaesthetic can significantly reduce pain/discomfort associated with the procedure. Active treatment (surgery or radiation) is mostly recommended for patients with localized disease and a long life expectancy with radical prostatectomy being the only treatment evaluated in a randomized controlled trial. Follow-up is at large based on prostate specific antigen (PSA) and a disease-specific history with imaging only indicated when symptoms occur. Cytotoxic therapy has become an option for selected patients with hormone refractory prostate cancer. The knowledge in the field of prostate cancer is rapidly changing. These EAU guidelines on prostate cancer summarize the most recent findings and put them into clinical practice.